

Puma Biotechnology (NASDAQ:PBYI) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been...
You can purchase shares of Puma Biotechnology (NASDAQ:PBYI) through any online brokerage.
Other companies in Puma Biotechnology’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Puma Biotechnology has a consensus price target of $6.50.
The stock price for Puma Biotechnology (NASDAQ: PBYI) is $7.9614 last updated November 6, 2026 at 5:49 PM EST.
There are no upcoming dividends for Puma Biotechnology.
Puma Biotechnology does not have any upcoming earnings scheduled.
There is no upcoming split for Puma Biotechnology.
Puma Biotechnology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for...